author-photo

Caroline Even

Institut Gustave Roussy

175

Papers

4722

Citations

Citation Trend

Filter By

Papers (121) Sort By

Journal Conference Others

LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetcs/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer.

2021 Clinical and Translational Science
Show All
- Source
- Cite
- Save
Citations (1)
435 Pegasus HNSCC, a platform study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL-2) with anti-cancer agents in patients with recurrent/metastatic head and neck squamous cell carcinoma

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
PO-0973 Locoregional treatment of primary tumor in synchronous metastatic HNSCC: A retrospective study

2021 Radiotherapy and Oncology
Show All
- Source
- Cite
- Save
Citations (0)
896P Long-responders to ICI in R/M-HNSCC: A retrospective multicentric French cohort

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Factors associated with under-reporting of head and neck squamous cell carcinoma in cause-of-death records: A comparative study of two national databases in France from 2008 to 2012.

2021 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (0)
Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma.

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
916P Impact of sarcopenia (S) on efficacy and toxicity of nivolumab (N) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in TOPNIVO (T) study

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (14)